Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses

CONCLUSIONS: This study provides novel fundamental data on proteins associated with response to mepolizumab or omalizumab in severe asthma and warrants further validation as potential biomarkers for therapy selection.PMID:38057814 | DOI:10.1186/s12931-023-02620-1

Source: Respiratory Care - December 7, 2023 Category: Respiratory Medicine Authors: Ayobami Akenroye Tanawin Nopsopon Laura Cho Matthew Moll Scott T Weiss Source Type: research